Back to News
Market Impact: 0.28
Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes
Source: Business Wire
Healthcare & BiotechPatents & Intellectual PropertyProduct Launches
Elvinix secured an exclusive license to Zealand Pharma's GLP-1/gastrin dual-agonist peptides for development of a regenerative therapy targeting type 1 diabetes. The licensing agreement expands Elvinix's therapeutic-development capabilities in a high-need diabetes indication, though no financial terms, clinical data, or development timeline were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ZEAL0.50
More News
- Backbone of a beast – charting Nvidia's rise to networking titan
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand